Diamondback Energy, Inc. Schedules Third Quarter 2024 Conference Call for November 5, 2024
September 25, 2024 16:01 ET
|
Diamondback Energy, Inc.
MIDLAND, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Diamondback Energy, Inc. (NASDAQ: FANG) (“Diamondback”), today announced that it plans to release third quarter 2024 financial results on November...
Armada Hoffler Announces Commencement of Public Offering of Common Stock
September 25, 2024 16:01 ET
|
Armada Hoffler Properties, Inc.
VIRGINIA BEACH, Va., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Armada Hoffler (NYSE: AHH) today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. The...
Viper Energy, Inc., a Subsidiary of Diamondback Energy, Inc., Schedules Third Quarter 2024 Conference Call for November 5, 2024
September 25, 2024 16:01 ET
|
Viper Energy, Inc.
MIDLAND, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”), a subsidiary of Diamondback Energy, Inc. (NASDAQ: FANG) (“Diamondback”), today announced that it plans...
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
September 25, 2024 16:01 ET
|
NuCana plc
EDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering...
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
September 25, 2024 16:01 ET
|
Abivax
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease...
ImPact Biotech to Present at Oppenheimer Private Life Sciences Company Showcase
September 25, 2024 16:01 ET
|
ImPact Biotech
TEL AVIV, Israel, Sept. 25, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a...
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
September 25, 2024 16:00 ET
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic...
FLUX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Flux Power Holdings, Inc. and Encourages Investors to Contact the Firm!
September 25, 2024 16:00 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Flux Power Holdings, Inc....
NFE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that New Fortress Energy Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 25, 2024 16:00 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been...
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
September 25, 2024 16:00 ET
|
INVENTIVA
Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for...
- September 25, 2024 15:51 ET Gleim Exam Prep Commemorates 50 Years of Academic Excellence and Community Support
- September 25, 2024 15:00 ET HOOPP President & CEO Jeff Wendling announces retirement